Chiaravalloti Agostino, Danieli Roberta, Lacanfora Annamaria, Palumbo Barbara, Caltagirone Carlo, Schillaci Orazio
Department of Biomedicine and Prevention, University Tor Vergata, viale Oxford 81, 00133, Rome, Italy.
Curr Alzheimer Res. 2017;14(2):154-160. doi: 10.2174/1567205013666160620114309.
In the last decade, several radiolabeled compounds have been developed for the imaging in vivo of amyloid pathology by means of Positron Emission Tomography (PET). Among these, 18F Florbetaben appear to be one of the most reliable for its high affinity for amyloid plaques in brain and its radio-chemical properties that make it usable in common clinical routine. The aim of this review is to provide a general overview of the application in vivo of 18F Florbetaben, describing for first the physiopathological basis of amyloid pathology. Afterwards, the chemical characteristics of this radiolabeled compound will be described, with a particular attention to the synthesis process and the kinetic in vivo. An overview on the imaging protocols and image interpretation will be provided as well and, as a last aspect, the results of the main studies performed in subjects with advanced and early AD will be summarized.
在过去十年中，已经开发出几种放射性标记化合物，用于通过正电子发射断层扫描（PET）对体内淀粉样蛋白病变进行成像。其中，18F 氟贝他宾因其对脑内淀粉样斑块具有高亲和力以及其放射化学性质使其可用于常规临床检查，似乎是最可靠的化合物之一。本综述的目的是对18F 氟贝他宾的体内应用进行总体概述，首先描述淀粉样蛋白病变的生理病理基础。之后，将描述这种放射性标记化合物的化学特性，特别关注合成过程和体内动力学。还将提供成像方案和图像解读的概述，最后，将总结在晚期和早期阿尔茨海默病（AD）患者中进行的主要研究结果。
